ML. Divergent effects of low-O 2 tension and iloprost on ATP release from erythrocytes of humans with type 2 diabetes: implications for O 2 supply to skeletal muscle. Am J Physiol Heart Circ Physiol 299: H566 -H573, 2010. First published May 28, 2010 doi:10.1152/ajpheart.00430.2010.-Erythrocytes release both O 2 and a vasodilator, ATP, when exposed to reduced O2 tension. We investigated the hypothesis that ATP release is impaired in erythrocytes of humans with type 2 diabetes (DM2) and that this defect compromises the ability of these cells to stimulate dilation of resistance vessels. We also determined whether a general vasodilator, the prostacyclin analog iloprost (ILO), stimulates ATP release from healthy human (HH) and DM2 erythrocytes. Finally, we used a computational model to compare the effect on tissue O 2 levels of increases in blood flow directed to areas of increased O2 demand (erythrocyte ATP release) with nondirected increases in flow (ILO). HH erythrocytes, but not DM2 cells, released increased amounts of ATP when exposed to reduced O2 tension (PO2 Ͻ 30 mmHg). In addition, isolated hamster skeletal muscle arterioles dilated in response to similar decreases in extraluminal O 2 when perfused with HH erythrocytes, but not when perfused with DM2 erythrocytes. In contrast, both HH and DM2 erythrocytes released ATP in response to ILO. In the case of DM2 erythrocytes, amounts of ATP released correlated inversely with glycemic control. Modeling revealed that a functional regulatory system that directs blood flow to areas of need (low O2-induced ATP release) provides appropriate levels of tissue oxygenation and that this level of the matching of O2 delivery with demand in skeletal muscle cannot be achieved with a general vasodilator. These results suggest that the inability of erythrocytes to release ATP in response to exposure to low-O2 tension could contribute to the peripheral vascular disease of DM2. muscle blood flow; red blood cells; oxygen delivery; prostacyclin CARDIOVASCULAR DISEASE ACCOUNTS for nearly half of deaths in humans with type 2 diabetes (DM2) (31, 41). It is estimated that in 2010 there will be in excess of 300 million cases of DM2 worldwide making this disease a major public health challenge (4). A significant complication of DM2 is impaired vascular function that contributes to a fourfold increased risk for claudication (4) and as much as a 16-fold increased risk for lower limb amputation (12,30,43). Although individuals with DM2 have an increased incidence of atherosclerosis in largeconduit vessels (4, 30), there is extensive evidence that microvascular circulatory control is also abnormal in humans with DM2 (23,24,27,35). Although direct studies of the skeletal muscle microcirculation are not possible in humans, such studies have been performed in several animal models of diabetes and reveal reduced convective O 2 delivery and diffusive O 2 transport that could contribute to a failure of the skeletal muscle vasculature to deliver appropriate amounts of O 2 to meet metabolic need bot...